Produktname:2-(2,6-Dichlorophenyl)acetonitrile

IUPAC Name:2-(2,6-dichlorophenyl)acetonitrile

CAS:3215-64-3
Molekulare Formel:C8H5Cl2N
Reinheit:95+%
Katalognummer:CM252193
Molekulargewicht:186.04

Packungseinheit Verfügbarer Vorrat Preis($) Menge
CM252193-100g in stock ƓŹ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

   refresh    

Produkt-Details

CAS-Nr.:3215-64-3
Molekulare Formel:C8H5Cl2N
Schmelzpunkt:-
SMILES-Code:C1=CC=C(C(=C1Cl)CC#N)Cl
Dichte:
Katalognummer:CM252193
Molekulargewicht:186.04
Siedepunkt:286.9°C at 760 mmHg
Mdl-Nr.:MFCD00001901
Lagerung:Store at room temperature.

Category Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Neflamapimod
Dementia with Lewy Bodies (DLB) is a rapidly progressive neurodegenerative disorder with a significant aging population and unmet health need. Alterations in p38 mitogen-activated protein kinases (MAPKs) are found to contribute to the neurodegenerative process in Alzheimer's disease (AD) and related dementias.
CervoMed’s Neflamapimod (VX-745) is an oral, brain penetrant, small molecule inhibitor of the protein kinase p38α. It is designed to specifically target the mechanisms that cause dysfunction and degeneration of neurons in the basal forebrain cholinergic system. Neflamapimod has the potential of reversing synaptic dysfunction in the basal forebrain. The positive phase 2a data was published in Nature Communications, Neurology, and JPAD. Neflamapimod was granted Fast Track Designation by the FDA for DLB, and phase 2b enrollment was completed in June, 2024.